Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

NCT ID: NCT02503657

Last Updated: 2026-01-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-03-09
• Study Completion Date: 2022-03-15

Brief Summary

This is a randomized, placebo-controlled, double-blind, 6-month study followed by a 6-month open-label extension phase to evaluate the efficacy, safety, and tolerability of MN-001 in patients diagnosed with moderate to severe idiopathic pulmonary fibrosis (IPF). Participants were randomly assigned to receive MN-001 or matching placebo twice daily over a 26-week period. A total of 15 participants were enrolled.

Detailed Description

This study was a single-center, randomized (2:1), placebo-controlled, double-blind, 6-month study followed by a 6-month open-label extension (OLE) phase in patients with moderate to severe IPF. Major inclusion criteria: physician diagnosed IPF (ATS Guidelines, 2011), males and females aged 21 to 80 years, GAP Stage II-III; on no anti-fibrotic treatment. Patients on stable dose of nintedanib for at least 3 months prior to the study were allowed.

The study consisted of a Screening Phase (up to 3 months prior to Day1), a 26- week Double-Blind Treatment (DBT) period, a 26-week Open-Label Extension (OLE) period, and a Follow-up / End of Study Visit (within 4 weeks of the last dose taken).

A total of 15 patients were enrolled in the study. During the DBT period, participants were randomly assigned to receive MN-001 750 mg twice daily or a matching placebo in a 2:1 ratio (MN-001: placebo) for 26 weeks. During the OLE period, all participants received MN-001 750 mg twice daily for 26 weeks. Taken together, participants (n=15) received either MN-001 50 mg twice daily for 12 months (MN-001/MN-001) or matching placebo for 6 months and MN-001 750 mg twice daily for 6 months (Placebo/MN-001).

Conditions

Idiopathic Pulmonary Fibrosis; IPF

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

MN-001 in Double-blind period for 26 weeks, then MN-001 in Open-Label period for 26 weeks

MN-001 750 mg twice a day during the double-blind period (26 weeks) and MN-001 750 mg twice a day during the open-label period for 26 weeks. The arm title is shortened to MN-001/MN-001 for all results sections.

Group Type: EXPERIMENTAL

MN-001

Intervention Type: DRUG

A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity

Placebo during Double-blind period for 26 weeks, then MN-001 in Open-Label period for 26 weeks

Placebo twice a day during the double-blind period for 26 weeks and MN-001 750 mg twice daily during the open-label period for 26 weeks. The arm title is shortened to Placebo/MN-001 for all results sections.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Excipients of MN-001/tipelukast

Interventions

MN-001

A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity

Intervention Type: DRUG

Placebo

Excipients of MN-001/tipelukast

Intervention Type: DRUG

Other Intervention Names

Tipelukast

Eligibility Criteria

Inclusion Criteria

• Male or female subjects ages 21 to 80, inclusive
• Presence of IPF confirmed per ATS criteria (2011)
• Presence of moderate to severe disease, stage II-III defined by GAP index (Gender, Age and Physiology)
• Subjects who are currently treated with OFEV™/Nintedanib should be on a stable dose for at least 3 months prior to initiation of the study drug.
• Females of child-bearing potential must have a negative serum ß-hCG (human chorionic gonadotropin) at screening and must be willing to use appropriate contraception (as defined by the investigator) for the duration of study treatment and 30 days after the last dose of study treatment.
• Males should practice contraception for the duration of study treatment and 30 days after the last dose of study treatment as follows: condom use and contraception by female partner.
• Subject is in stable condition on the basis of medical history, physical examination, and laboratory screening, as determined by the investigator.
• Subject is willing and able to comply with the protocol assessments and visits, in the opinion of the study nurse/coordinator and the Investigator.
• Written informed consent is obtained prior to participating the study.

Exclusion Criteria

• Expected to receive a lung transplant within 1 year from the start of the Treatment Phase or on a lung transplant waiting list at the start of the Treatment Phase.
• Known explanation for interstitial lung disease
• Subjects on OFEV™/Nintedanib with a dose interruption due to significant adverse events within 6 weeks of screening visits.
• Ongoing IPF treatments with investigational therapy
• Ongoing IPF treatments with Esbriet® (Pirfenidone)
• Immunosuppressants (i.e., Mycophenolate, Imuran, Cyclophosphamide), and cytokine modulating agents within 1 month of Screening Visit and throughout the study
• Use of antibiotics and systemic steroids due to IPF exacerbation within 1 month of Screening Visit
• Clinically significant cardiovascular disease, including myocardial infarct within last 6 months, unstable ischemic heart disease, congestive heart failure or angina
• Resting pulse < 50 bpm, SA (sinoatrial) or AV (atrioventricular) block, uncontrolled hypertension, or QTcF (QT interval corrected using the Fridericia formula) > 450 ms
• Immune system disease
• Any significant laboratory abnormality which, in the opinion of the Investigator, may put the subject at risk
• History of malignancy < 5 years prior to signing the informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
• History or evidence of drug or alcohol abuse
• History of HIV (human immunodeficiency virus) or other active infection.
• Currently has a clinically significant medical condition including the following: neurological, psychiatric, immunological, metabolic, hepatic, hematological, pulmonary (other than IPF) , cardiovascular (including uncontrolled hypertension), gastrointestinal, urological disorder, or central nervous system (CNS) infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study.

Note: Active medical conditions that are minor or well-controlled are not exclusionary if, in the judgment of the Investigator, they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted.

• CYP2C8 (cytochrome P450 isoenzyme C28) and CYP2C9 (cytochrome P450 isoenzyme C29) substrates with narrow therapeutic indices (i.e. paclitaxel, phenytoin and S-warfarin) within 14 days of Screening Visit and throughout the study.
• Beta blockers within 14 days of Screening Visit and throughout the study
• Macrolide or quinolone class antibiotics within 14 days of Screening Visit and throughout the study.
• Poor peripheral venous access that will limit the ability to draw blood as judged by the Investigator.
• Currently participating, or has participated in, a study with an investigational or marketed compound or device within 3 months prior to signing the informed consent.
• Unwilling or unable to conduct Spirometry (Vital Capacity) test.
• Unable to cooperate with any study procedures, unlikely to adhere to the study procedures and keep appointments, in the opinion of the Investigator, or is planning to relocate during the study.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MediciNova

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rebecca Bascom, MD

Role: PRINCIPAL_INVESTIGATOR

PSU Research, Department of Medicine

Locations

Penn State University College of Medicine, Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Informed Consent Form

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

MN-001-IPF-201

Identifier Type: -

Identifier Source: org_study_id